Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30054633HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054634HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054635HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054636HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054637HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054638HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054639HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30020633HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054640HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TVIS30054641HIVENSG00000157540.22protein_codingDYRK1ANoNo1859Q13627
TCGA Plot Options
Drug Information
GeneDYRK1A
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0004012
UniProt IDQ13627
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830